This study is the first report indicating the high correlation between SMYD3‐mediated methylation and HER2 homodimerization, supporting that the development of specific inhibitors targeting SMYD3 methylation pathway will be a promising approach for development of a novel class of anti‐cancer therapy. This evidence concerns the gene ERBB2 and cancer.